Merck Announces Presentation of Phase III Investigational Studies Evaluating … – MarketWatch (press release)

Merck Announces Presentation of Phase III Investigational Studies Evaluating …
MarketWatch (press release)
DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the …

and more »